|
|
|
|
|
|
|
|
|
05.08.25 - 13:06
|
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code (Business Wire)
|
|
|
Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of approximately $43 million.
ANKTIVA® Unit Growth Since J-code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024.
Cash Position: $153.7 million in cash, cash equivalents and marketable securities as of June 30, 2025, with additional $80 million equity financing closed in July 2025, with warrants which could result in an additional gross proceeds of up to approximately $96.0 million.
Non-Small Cell Lung Cancer (NSCLC): ImmunityBio has launched ResQ201A, a randomized controlled trial (RCT), in the U.S., evaluating its IL-15 superagonist N-803 in combination with tislelizumab, a PD-1 CPI from BeOne Medicines in patients with second-line lung cancer who were progressing on checkpoint inhibitors (CPIs). The Company has also submitted clinical trial applications for ResQ201A in the EU and the UK, with Canada expected to be submitted in early Q3 2025, and with plans underway to s...
|
|
|
|
|
|
|
25.07.25 - 12:06
|
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors (Business Wire)
|
|
|
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million.
Piper Sandler & Co. is acting as the exclusive placement agent for the registered direct offering.
The securities to be sold by the Company are offered under its automatic shelf registration statement on F...
|
|
|
|
|
|
|
|
|
|
|
12.05.25 - 12:33
|
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code (Business Wire)
|
|
|
For the three months ended March 31, 2025—marking the first quarter with a permanent J-code that streamlined billing and reimbursement for prescribing providers—ImmunityBio achieved net product revenue of approximately $16.5 million, representing a 129% increase over $7.2 million in Q4 2024.
ANKTIVA® unit sales volume in Q1 2025 grew 150% over Q4 2024, with monthly volume in March up 69% over February.
Nearly 200 urology practices across the United States are in the process of registering for ImmunityBio's recombinant BCG (rBCG) Expanded Access Program (EAP), reflecting continued progress in ImmunityBio's efforts to address the Bacillus Calmette-Guérin (BCG) shortage and broaden the market for ANKTIVA.
At the recent American Urological Association Annual Meeting (AUA 2025), the company announced positive long-term results from the QUILT 3.032 study that showed the longest duration of complete response and highest rate of cystectomy avoidance within the non-muscle invasive bladder cancer (NMIBC) sp...
|
|
|
|
|
|
|
08.04.25 - 13:33
|
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor (Business Wire)
|
|
|
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $75 million before deducting any offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $90 million.
The securities to be sold by the Company are offered under its automatic shelf registration statement on Form S-3 (Registration No. 333-278770). A final prospectus supplement, which contains additional information relating to th...
|
|
|
|
|
27.03.25 - 23:15
|
"This Is Existential": Billionaire Cancer Researcher Says Covid & Vaccine Likely Causing Surge In Aggressive Cancers (ZeroHedge)
|
|
|
"This Is Existential": Billionaire Cancer Researcher Says Covid & Vaccine Likely Causing Surge In Aggressive Cancers
Dr. Patrick Soon-Shiong - a transplant surgeon-turned-biotech billionaire renowned for inventing the cancer drug Abraxane - has issued a startling warning in a new in-depth interview with Tucker Carlson.
Soon-Shiong, founder of ImmunityBio ($IBRX) and owner of the Los Angeles Times, claims that the COVID-19 pandemic, and the very vaccines developed to fight it, may be contributing to a global surge in “terrifyingly aggressive” cancers. In the nearly two-hour conversation, the Los Angeles Times owner leveraged his decades of clinical and scientific experience to outline why he suspects an unprecedented cancer epidemic is unfolding. This report examines Dr. Soon-Shiong's background and assertions, the scientific responses for and against his claims, new data on post-COVID health trends, and the far-reaching implications if his alarming hypothesis proves true.
Dr. So...
|
|
|
|
|
03.03.25 - 13:33
|
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 (Business Wire)
|
|
|
With a permanent J-code (J9028) awarded in January 2025, ImmunityBio's February 2025 ANKTIVA® unit sales volume grew 97% over unit sales volume in December 2024
ANKTIVA sales momentum continues to trend upward quarter to date 2025, with sales volume in February representing a 67% increase month-over-month from January
Sales volume in the 2 months in 2025 to date shows a 69% increase over the sales volume in the 2 months prior (November and December 2024) and already exceeds the total units for all of Q4 2024
For the three-month period ending December 31, 2024 prior to permanent J-code approval, ImmunityBio achieved net product revenue of approximately $7.2 million, surpassing net product revenue of $6.0 million in the prior quarter, a 21% quarter over quarter increase
FDA authorization of expanded access of an alternative source of BCG in February 2025 is expected to address the issue of BCG shortage with over 45,000 doses available
Over 60 sites are now being activated to receive recombinant BCG (rBCG)...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
